DM management
Reading File
Finding Sources
Finding Sources
Searching PubMed
"diabetes mellitus"[MeSH Terms] AND "management"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from Harrison's and Rosen's. Let me compile the complete DM management overview:
Diabetes Mellitus (DM) - Management
Sources: Harrison's Principles of Internal Medicine 22E (2025), Rosen's Emergency Medicine, Textbook of Family Medicine
Overall Goals of Therapy
The three core goals of DM management are:
- Eliminate symptoms of hyperglycemia
- Reduce long-term microvascular and macrovascular complications
- Allow as normal a lifestyle as possible
Key targets:
- HbA1c < 7% (individualized; may be relaxed in elderly, comorbid patients)
- Fasting blood glucose: 90-130 mg/dL
- Symptoms generally resolve when plasma glucose < 200 mg/dL
1. Multidisciplinary Team Approach
Care requires a Chronic Care Model with a proactive, team-based approach:
- Primary care provider / Endocrinologist / Diabetologist
- Certified diabetes educator
- Nutritionist / Dietitian
- Pharmacist
- Behavioral health professional / Social worker
- Subspecialists for complications (ophthalmologist, neurologist, nephrologist, cardiologist, podiatrist)
2. Monitoring
| Parameter | Frequency |
|---|---|
| HbA1c | 2-4 times/year |
| Continuous glucose monitoring (CGM) or fingerstick | Daily |
| Blood pressure | Every visit |
| Lipids | Annually |
| Urine albumin/creatinine | Annually |
| Foot exam | Every visit |
| Ophthalmology exam | Annually (Type 1: 5 yrs after diagnosis; Type 2: at diagnosis) |
| Dental exam | Twice yearly |
| Vaccinations | Influenza, pneumococcal, COVID-19, hepatitis B |
3. Lifestyle Management
Nutrition (Medical Nutrition Therapy - MNT)
- Type 1 DM: Adjust insulin to carbohydrate intake using insulin-to-carbohydrate ratios; minimize weight gain; allow dietary flexibility
- Type 2 DM: Weight loss is primary goal (target ≥5-10%); modest caloric reduction, low-glycemic-index foods, high fiber; very-low-carbohydrate diets may achieve rapid early glucose control
- Sodium < 2,300 mg/day
- No routine vitamin/antioxidant supplements (insufficient evidence)
- Vitamin D/calcium as for general bone health
Physical Activity
- 150 min/week of moderate aerobic exercise (≥3 days, no gaps >2 days) - ADA recommendation
- Include resistance training, flexibility/balance exercises
- Reduces cardiovascular risk, blood pressure, body fat; improves insulin sensitivity
- Caution in Type 1 DM: Risk of both hypo- and hyperglycemia during exercise depending on pre-exercise glucose and insulin levels
4. Pharmacologic Management
Type 2 DM - Oral Agents
| Class | Drugs | Mechanism | Notes |
|---|---|---|---|
| Biguanides | Metformin | ↓ Hepatic glycogenolysis/gluconeogenesis | First-line; no weight gain; ↓HbA1c ~1.5%; avoid if GFR <30 |
| Sulfonylureas | Glipizide, Glimepiride, Glyburide | Stimulate pancreatic insulin release | Risk of hypoglycemia; 2nd-line add-on |
| Thiazolidinediones (TZDs) | Pioglitazone, Rosiglitazone | Insulin sensitizers; ↓ hepatic gluconeogenesis | Increased cardiac risk with rosiglitazone; weight gain; fluid retention |
| Meglitinides | Repaglinide, Nateglinide | Stimulate postprandial insulin release | Take with meals only |
| DPP-4 Inhibitors | Sitagliptin, Saxagliptin | Inhibit incretin degradation | Weight-neutral; well-tolerated |
| GLP-1 Receptor Agonists | Semaglutide, Liraglutide, Dulaglutide | Enhance incretin effect, slow gastric emptying | Weight loss benefit; CV protection; injectable or oral (semaglutide) |
| SGLT-2 Inhibitors | Empagliflozin, Dapagliflozin, Canagliflozin | Block renal glucose reabsorption | Weight loss; CV + renal protection; risk of UTI/genital infections |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol | Slow carbohydrate absorption | GI side effects; modest efficacy |
Step-up approach:
- Start metformin + lifestyle
- If HbA1c goal not met at 3 months → add second agent (preferred: GLP-1 agonist if CVD/weight loss needed; SGLT-2 if HF/CKD; sulfonylurea if cost is concern)
- Triple therapy or add insulin as needed
Type 1 DM - Insulin Therapy
Insulin is mandatory for all Type 1 DM patients.
Insulin Types:
| Type | Examples | Onset | Peak | Duration |
|---|---|---|---|---|
| Rapid-acting | Lispro, Aspart, Glulisine | 5-15 min | 30-90 min | 3-5 h |
| Short-acting | Regular insulin | 30-60 min | 2-3 h | 5-8 h |
| Intermediate-acting | NPH | 1-2 h | 4-8 h | 10-18 h |
| Long-acting | Glargine (U-100/U-300), Detemir | 1-2 h | Minimal | ~24 h |
| Ultra-long-acting | Degludec | 30-90 min | Minimal | ~42 h |
Intensive Insulin Therapy:
- Basal-bolus regimen: long-acting insulin (glargine or degludec once daily) + rapid-acting analogue before meals
- Dose adjusted based on carbohydrate intake, blood glucose, and planned activity
- Benefits: reduced microvascular complications (DCCT trial), improved glycemic control
Technology:
- CGM (Continuous Glucose Monitor): Updates glucose every 5 minutes; reduces hypoglycemia; preferred in Type 1 DM
- Insulin pumps (CSII): Continuous subcutaneous insulin infusion; preferred by some patients; tight glycemic control
- Hybrid closed-loop systems (Artificial Pancreas): CGM + pump with algorithm; not fully automated - patient must input carbohydrate data
- Initial basal insulin in Type 2 DM: Glargine/Detemir/NPH at 0.1-0.2 units/kg/day (~10 units) with follow-up in 3-4 days
5. Management of Specific Complications
Diabetic Ketoacidosis (DKA) - Type 1 DM Emergency
- IV fluids, insulin infusion, electrolyte replacement (K+), monitoring
- Treat precipitating cause (infection, missed insulin)
Hyperosmolar Hyperglycemic State (HHS) - Type 2 DM Emergency
- Aggressive fluid resuscitation, correction of electrolytes, insulin
Hypoglycemia
- Tight control increases risk
- Treat with 15g fast-acting carbohydrates (conscious) or IV dextrose/IM glucagon (unconscious)
6. Cardiovascular & Renal Risk Reduction
- Hypertension target: <130/80 mmHg; ACE inhibitors or ARBs preferred (also nephroprotective)
- Dyslipidemia: Statin therapy for most adults with DM >40 years; LDL goal <70 mg/dL in high-risk
- Antiplatelet: Aspirin for secondary prevention (≥50 years with CVD risk factors)
- GLP-1 agonists and SGLT-2 inhibitors have proven cardiovascular and renal outcome benefits (EMPA-REG, LEADER, DECLARE trials)
7. Pancreas Transplantation
- Combined pancreas-kidney transplant for Type 1 DM with end-stage renal disease
- Graft survival >75% at 1 year at specialized centers
- Complications: rejection, post-transplant pancreatitis, graft thrombosis, immunosuppression side effects
- Can ameliorate nephropathy, neuropathy, retinopathy, gastroparesis
Recent Evidence (2025)
Two recent systematic reviews worth noting:
- Wilson et al., Diabetes Care 2025 (PMID 40117466) - a systematic review of clinical practice guidelines on inpatient DM/hyperglycemia management highlights significant variation across guidelines, suggesting individualized inpatient targets remain an area of evolving evidence.
- Li et al., BMC Primary Care 2025 (PMID 39966713) - confirms that specialist integration in primary care teams significantly improves HbA1c control in DM patients.
Key Takeaways:
- Comprehensive diabetes care goes beyond glucose control - it addresses CV risk, renal protection, eye/foot care, and patient education
- Metformin remains first-line for Type 2 DM; GLP-1 agonists and SGLT-2 inhibitors are now preferred second agents, especially with CVD/CKD
- All Type 1 DM patients need insulin; CGM and closed-loop systems are increasingly standard
- Individualized HbA1c targets and shared decision-making are central to modern DM care
This is a shared conversation. Sign in to Orris to start your own chat.